Suppr超能文献

最佳血糖目标值在动脉瘤性蛛网膜下腔出血患者中的应用:一项配对队列研究。

Optimal Glucose Target After Aneurysmal Subarachnoid Hemorrhage: A Matched Cohort Study.

机构信息

Section of Neurosurgery, Department of Clinical Neurosciences, University of Calgary, Calgary, Canada.

Cumming School of Medicine, University of Calgary, Calgary, Canada.

出版信息

Neurosurgery. 2022 Mar 1;90(3):340-346. doi: 10.1227/NEU.0000000000001823. Epub 2021 Dec 30.

Abstract

BACKGROUND

Hyperglycemia has been associated with poor outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). However, there remains debate as to what optimal glucose targets should be in this patient population.

OBJECTIVE

To assess whether we could identify an optimal glucose target for patients with aSAH.

METHODS

We performed a post hoc analysis of the "clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage" trial data set. Patients had laboratory results drawn daily for the entirety of their intensive care unit stay. Maximum blood glucose levels were assessed for a relationship with unfavorable outcomes using multiple logistic regression analysis. Maximum blood glucose levels were dichotomized based on the Youden index, which identified a maximum level of <9.2 mmol/L as the optimal cut point for prediction of unfavorable outcomes. Nearest neighbor matching was used to assess the relationship between maintaining glucose levels below the cut point and unfavorable functional outcomes (defined as a modified Rankin score of >2 at 3 mo post-aSAH). The matching was performed after calculation of a propensity score based on identified predictors of outcome and glucose levels.

RESULTS

Three hundred eighty-nine patients were included in the matched analysis. Propensity scores were balanced on both the covariates and outcomes of interest. There was a significant average treatment effect (-0.143: 95% confidence interval -0.267 to -0.019) for patients who maintained glucose levels <9.2 mmol/L.

CONCLUSION

Maintaining glucose levels below the identified cut point was associated with a decreased risk for unfavorable outcomes in this retrospective matched study.

摘要

背景

高血糖与动脉瘤性蛛网膜下腔出血(aSAH)患者的不良预后相关。然而,在该患者人群中,最佳血糖目标值仍存在争议。

目的

评估我们是否可以确定 aSAH 患者的最佳血糖目标值。

方法

我们对“clazosentan 以克服蛛网膜下腔出血后发生的神经缺血和梗死”试验数据集进行了事后分析。患者在整个重症监护病房期间每天进行实验室检查。使用多变量逻辑回归分析评估最大血糖水平与不良结局的关系。根据 Youden 指数将最大血糖水平进行二分法,确定<9.2mmol/L 作为预测不良结局的最佳切点。使用最近邻匹配法评估将血糖水平维持在切点以下与不良功能结局(定义为 aSAH 后 3 个月改良 Rankin 评分>2)之间的关系。在根据结局和血糖水平的预测因素计算倾向评分后,进行匹配。

结果

389 例患者纳入匹配分析。倾向评分在协变量和感兴趣的结局上均得到平衡。血糖水平<9.2mmol/L 的患者的平均治疗效果显著(-0.143:95%置信区间-0.267 至-0.019)。

结论

在这项回顾性匹配研究中,将血糖水平维持在确定的切点以下与不良结局的风险降低相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验